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Abstract Bone morphogenetic protein-2 (BMP-2) regulates
development of heart during vertebrate embryogenesis. In vitro
BMP-2 induces di¡erentiation of precardiac cells into mature
cardiomyocytes by inducing the expression of cardiac-speci¢c
genes. However, the role of BMP-2 and its signaling in other
cardiac functions have not been studied. We examined the ac-
tion of phosphatidylinositol (PI) 3 kinase in isolated adult rat
cardiomyocytes. Incubation of rat ventricular cardiomyocytes
with BMP-2 increased the PI 3 kinase activity. Ly294002, a
pharmacological inhibitor of PI 3 kinase, blocked BMP-2-in-
duced PI 3 kinase activity completely. To investigate the con-
tractility of isolated cardiomyocytes, fractional shortening was
examined. BMP-2 signi¢cantly increased the percent fractional
shortening of the cardiomyocytes. Inhibition of PI 3 kinase
activity completely abolished this action of BMP-2. These
data indicate that PI 3 kinase regulates BMP-2-induced myo-
cyte contractility. To further con¢rm this observation, we used
adenovirus-mediated gene transfer to express a constitutively
active myristoylated catalytic subunit of PI 3 kinase in rat
cardiomyocytes. Infection of cardiomyocytes with the adenovi-
rus vector increased the expression of constitutively active PI 3
kinase within 24 h. Expression of constitutively active PI 3 ki-
nase signi¢cantly increased cardiomyocyte contractility. To-
gether, these data show for the ¢rst time that the growth and
di¡erentiation factor, BMP-2, stimulates cardiomyocyte con-
tractility. Also we provide the ¢rst evidence that BMP-2-in-
duced PI 3 kinase activity regulates this cardiomyocyte func-
tion.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Bone morphogenetic proteins (BMPs) constitute a subclass
of the TGFL super family of proteins and were originally
identi¢ed in the extracts of demineralized bone [1]. BMP-2,
a member of this family of protein, similar to its Drosophila
homolog dpp, is an important growth and di¡erentiation fac-
tor, which regulates di¡erentiation of cardiogenic mesoderm
in vertebrates [2]. Homozygous inactivation of BMP-2 allele
in mouse results in embryonic lethality due to abnormal heart
development [3]. Similar to the functional role of BMP-2 in
vivo, it has been demonstrated that this growth and di¡er-
entiation factor induces di¡erentiation of P19 teratocarcinoma
cells into mature cardiomyocytes with concomitant expression
of cardiac-speci¢c transcription factors [4].
BMP-2 exerts its biological e¡ects via type I and type II
serine threonine kinase receptors [5,6]. Binding of BMP-2 to
the receptor induces oligomerization of the receptor com-
plexes resulting in increased serine threonine kinase activity
of the type I receptor, which recruits and phosphorylates the
BMP receptor-speci¢c R-Smads, Smad 1, Smad 5 and Smad 8
[5^7]. Upon phosphorylation, the R-Smad heterodimerizes
with co-Smad, Smad 4 and translocates to the nucleus, where
it associates with tissue-speci¢c transcription factors and co-
activators and acts as a transcription factor to induce speci¢c
genes required for the biological activity of BMP-2 [5^9].
BMP-2-soaked beads when implanted into non-precardiac
mesoderms in chicks induced cardiac-speci¢c transcription
factors Nkx2.5 and GATA-4 [10]. Furthermore, induction of
these transcription factors was also observed during BMP-2-
induced di¡erentiation of precardiac cells into mature cardio-
myocytes [4]. It is established that major signal transduction
pathways used by BMPs to induce tissue-speci¢c genes are
mediated by Smads [8,11]. However, BMP-2 has been re-
ported to activate mitogen-activated protein kinase (MAPK)
pathways including Erk1/2 and p38 MAPK [12]. We have
recently shown that in preosteoblasts, BMP-2 stimulates phos-
phatidylinositol (PI) 3 kinase, as one of the contributors of
many signaling cascades, that regulates di¡erentiation of these
cells into mature osteoblasts [13].
Heart failure is a result of multiple positive and negative
signaling pathways, which regulate physiologically complex
biological responses including myocytes contractility [14].
Thus one of the major causes of heart dysfunction is the
loss of responsiveness of myocytes to contractility [15].
Although a role of BMP-2 and BMP-speci¢c Smads in cardiac
development in vertebrate and cardiomyocyte di¡erentiation
in vitro has been established, its role in other cardiomyocyte
function has not been investigated. In this study, we show that
BMP-2 increases PI 3 kinase activity in isolated rat ventricular
cardiomyocytes. We demonstrate, for the ¢rst time, that
BMP-2 stimulates myocyte fractional shortening. Further-
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more, we provide the ¢rst evidence that PI 3 kinase regulates
BMP-2-induced myocyte shortening.
2. Materials and methods
2.1. Materials
Tissue culture reagents were obtained from Life Technologies, Inc.
Recombinant BMP-2 was obtained from Genetics Institute, Cam-
bridge, MA, USA. NP-40, Na3VO4, phenylmethylsulfonyl£uoride
and actin antibody were purchased from Sigma. Aprotinin was ob-
tained from Bayer. Antibody against the p85 subunit and p110 sub-
unit of PI 3 kinase were obtained from Santa Cruz Biotechnology. Ad
Myr-p110 adenovirus vector expressing constitutively active p110 cat-
alytic subunit of PI 3 kinase was a kind gift from Dr. Wataru Ogawa,
Kobe University, Japan.
2.2. Cell culture
Calcium-tolerant myocytes were isolated from male WKY rats
(V200 g) using the method of Piper et al. with modi¢cations [16^
18]. Brie£y, after deep anesthesia hearts were rapidly removed and
mounted via the aorta onto a cannula attached to a Langendor¡-
type apparatus allowing retrograde perfusion of the coronary arteries.
Hearts were perfused for 5 min with 37‡C sterile-¢ltered calcium-free
Krebs^Ringers^bicarbonate bu¡er (KRB; 110 mM NaCl, 2.6 mM
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM
glucose and 30 mM 2,3-butanedione monoxime) at 80 mm Hg. Hearts
were then perfused for 15^20 min with KRB enzyme solution con-
taining 0.5 mg/ml type II collagenase, 25 mM CaCl2 and 1 mg/ml
fatty acid-free albumin. After digestion, the ventricles were trimmed
free and minced in KRB enzyme solution containing 1 mg/ml albu-
min. Tissues were then ¢ltered through a nylon mesh and sedimented
by centrifugation at 25Ug for 90 s. Cells were resuspended in 10 ml
pre-warmed, gas-equilibrated KRB containing 25 WM calcium, and
allowed to sediment by gravity for 15 min. This step was repeated
with KRB containing 50, 100, 250 and 500 WM calcium. Cells were
then incubated on 100 mm polystyrene culture dishes for 2 h at 37‡C
with 5% CO2 atmosphere with a 1:1 mixture of KRB with 500 WM
calcium and ACM medium (M199 medium with 0.5% bovine serum
albumin (BSA)). Non-adherent cells were removed, washed and re-
plated in laminin-coated T25 culture £asks with ACM medium con-
taining 4% fetal bovine serum. The myocytes were then replated at
250 000 cells/T25 £ask in fresh M199 medium containing 0.5% BSA.
2.3. Adenovirus infection
Ventricular cardiomyocytes were infected with Ad Myr-p110 at 50
MOI (multiplicity of infection), essentially as described [13,19].
2.4. Immunoprecipitation, immunoblotting and PI 3 kinase assay
Cells were lysed in RIPA bu¡er (20 mM Tris^HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 0.05% aprotinin
and 1% NP-40). Cleared cell lysates were prepared by centrifugation
at 10 000Ug for 30 min at 4‡C to separate the debris. Protein con-
centration was determined in the lysate. An equal amount of protein
was immunoprecipitated with p85 regulatory subunit of PI 3 kinase as
described [13,19]. The immunoprecipitates were used in immunocom-
plex-associated PI 3 kinase assay using PI as substrate in the presence
of [Q-32P]ATP. The reaction products were separated by thin layer
chromatography. 32P-labeled PI 3-phosphate was visualized by auto-
radiography as described [20,21]. Immunoblotting of the lysates was
performed using appropriate antibodies as described previously
[13,19].
2.5. Measurement of myocyte shortening
Contractile properties of isolated ventricular myocytes were as-
sessed by measuring fractional shortening of single cell cardiomyo-
cyte. The coverslips with attached cells were placed in a tempera-
ture-controlled chamber at 37‡C and superfused with bu¡er
containing 100 ng/ml BMP-2. Myocytes were ¢eld-stimulated with
5 ms pulses at 0.5 Hz. Cardiomyocyte shortening and relengthening
was measured on the stage of an inverted phase-contrast microscope
(Nikon Eclipse TE 200) using an optical video system in which the
myocyte analog motion signal was digitized and analyzed by a com-
puter. Measurements were performed on three to ¢ve individual car-
diomyocytes in each experimental group and represented as mean
percent fractional shortening.
2.6. Statistical analysis
Data are expressed as meanPS.E.M. Statistical signi¢cance was
assessed by Student’s unpaired t-test. Signi¢cance was determined as
probability (P) value less than 0.05.
3. Results
3.1. BMP-2 stimulates PI 3 kinase activity in cardiomyocytes
To investigate the role of BMP-2 in cardiomyocyte func-
tion, we isolated cardiomyocytes from an adult rat. These
freshly prepared cells maintain normal signaling responses in-
cluding contraction characteristics upon electrical stimuli,
thereby demonstrating Ca2þ-dependent excitation^contraction
coupling [16,22]. To examine PI 3 kinase activity, ventricular
myocytes were incubated with BMP-2. Cell lysates were im-
munoprecipitated with an antibody that recognizes the regu-
latory p85 subunit of PI 3 kinase. The immunoprecipitates
were used in immunocomplex PI 3 kinase assay. Appreciable
basal PI 3 kinase activity was observed in these ventricular
myocytes (Fig. 1, lane 1). However, BMP-2 signi¢cantly in-
creased the PI 3 kinase activity (Fig. 1, compare lane 2 with
lane 1). Treatment of ventricular cardiomyocytes with the
pharmacological inhibitor of PI 3 kinase, Ly294002, followed
by incubation with BMP-2 completely blocked BMP-2-in-
duced PI 3 kinase activity (Fig. 1, compare lane 4 with lane 2).
3.2. BMP-2 regulates cardiomyocyte contractility
One of the physiological responses of cardiomyocytes is
to exhibit shortening and relengthening upon activation. In
many cardiovascular diseases, myocyte dysfunction is due to
lack of shortening. We examined the e¡ect of BMP-2 on
shortening of isolated ventricular cardiomyocytes. The cells
were incubated with BMP-2 and cardiomyocyte shortening
was measured using a phase-contrast microscope attached to
BMP-2
Ly294002
-               +                  -                 +
-                -                 +                 +
PI 3-P
1               2                 3                   4
Fig. 1. E¡ect of BMP-2 on PI 3 kinase activity. Rat ventricular my-
ocytes were prepared as described in Section 2. Cardiomyocytes
were treated with 12.5 WM Ly294002 for 1 h before incubation with
BMP-2 for 15 min. Cleared cell lysates were immunoprecipitated
with anti-p85 regulatory subunit antibody of PI 3 kinase. Immuno-
complex PI 3 kinase assay was performed as described in Section 2.
The arrow indicates the position of PI 3-phosphate.
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an optical video system in which the cardiomyocyte motion
was analyzed by a computer. BMP-2 signi¢cantly increased
the fractional shortening (Fig. 2). These data for the ¢rst time
demonstrate that along with the established cardiogenic role
of BMP-2, this growth and di¡erentiation factor also plays an
important role in myocyte shortening.
3.3. PI 3 kinase regulates cardiomyocyte shortening
To examine the role of PI 3 kinase in BMP-2-induced car-
diomyocyte shortening, we used the PI 3 kinase inhibitor
Ly294002, which abolished BMP-2-induced PI 3 kinase activ-
ity completely (Fig. 1). Isolated rat cardiomyocytes were
treated with Ly294002 before incubation with BMP-2. The
fractional shortening was determined in these cells. Inhibition
of PI 3 kinase signi¢cantly prevented BMP-2-induced frac-
tional shortening (Fig. 2). These data indicate that PI 3 kinase
regulates BMP-2-induced shortening of cardiomyocytes. To
con¢rm the involvement of PI 3 kinase, we used myristoylated
p110 catalytic subunit of PI 3 kinase (Myr-p110), which acts
as a constitutively active kinase. An adenovirus vector ex-
pressing Myr-p110 (Ad Myr-p110) was used to infect rat ven-
tricular cardiomyocytes for 24 h. Immunoblot analysis of cell
lysates using anti-p110 antibody showed high basal expression
of the PI 3 kinase catalytic subunit (Fig. 3A, lane 1). How-
ever, infection of Ad Myr-p110 yielded appreciable expression
of the constitutively active catalytic subunit at 24 h (Fig. 3A,
compare lane 2 with lane 1). Myocyte shortening was mea-
sured in these adenovirus vector-infected primary cardiomyo-
cytes. Expression of the constitutively active PI 3 kinase cata-
lytic subunit signi¢cantly increased fractional shortening (Fig.
3B). These data provide the ¢rst evidence that PI 3 kinase
regulates BMP-2-induced cardiomyocyte contractility.
4. Discussion
A signi¢cant ¢nding of this study is that BMP-2 activates
PI 3 kinase activity in cardiomyocytes. We demonstrate for
the ¢rst time that the cardiogenic growth and di¡erentiation
factor BMP-2 stimulates cardiomyocyte shortening. Further-
more, we provide the ¢rst evidence that PI 3 kinase signaling
regulates BMP-2-induced shortening of cardiomyocytes.
One major biological function of BMP-2 in vertebrates is
cardiogenesis during embryonic development [3]. Also BMP-2
acts as survival factor for neonatal cardiac myocytes via Smad
1, the downstream target of BMP receptor [23]. This action of
BMP-2 was ascribed to the antiapoptotic function BMP-2
[23]. Apart from this, any other function of BMP-2 in cardiac
function has not been described. Here we demonstrate for the
¢rst time that BMP-2 increases cardiomyocyte shortening
(Fig. 2).
PI 3 kinase functions as a focal point in receptor and non-
receptor tyrosine kinase- and G-protein-coupled receptor-
mediated signal transduction resulting in various cell func-
tions, which include proliferation, secretion, migration, surviv-
al, di¡erentiation and membrane ru¥ing [24,25]. Also PI 3
kinase has been implicated in several TGFL-induced biologi-
cal activities, which include epithelial and endothelial cell sur-
vival and in epithelial to mesenchymal transition [26^28].
These ¢ndings indicate that activation of serine threonine ki-
nase receptor also utilizes this central lipid kinase pathway.
Indeed we have recently shown that BMP-2 receptor stimula-
tion results in activation of PI 3 kinase in preosteoblasts. Also
we showed that PI 3 kinase signaling regulates di¡erentiation
of osteoblasts [13]. Now we show that activation of BMP-2
receptor serine threonine kinase in cardiomyocytes activates
PI 3 kinase (Fig. 1).
A role of PI 3 kinase has been implicated in cardiac hyper-
Fig. 2. Inhibition of PI 3 kinase blocks fractional shortening of car-
diomyocytes. Rat ventricular myocytes were treated with Ly294002
before incubating with BMP-2. The myocyte shortening was mea-
sured as described in Section 2. *P6 0.05 vs. BMP-2 unstimulated.
**P6 0.05 vs. BMP-2 alone.
Fig. 3. Constitutively active PI 3 kinase regulates cardiomyocyte
contractility. A: Expression of constitutively active PI 3 kinase in
cardiomyocytes. Ventricular cardiomyocytes were infected with 50
MOI of Ad Myr-p110 for 24 h as described [13,19]. The cleared cell
lysates were immunoblotted with anti-p110 antibody. The bottom
panel shows immunoblot analysis of the samples with actin anti-
body. B: Constitutively active PI 3 kinase increases fractional short-
ening of the cardiomyocytes. Ventricular cardiomyocytes were in-
fected with Ad Myr-p110 or with a control virus Ad GFP for 24 h.
The shortening of the cardiomyocytes was measured as described in
Section 2. *P6 0.05 vs. Ad GFP-infected cells.
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trophy induced by various agonists [29^32]. Moreover, PI 3
kinaseQ, the speci¢c isotype activated by G-protein-coupled
receptors, is activated in pressure overload-induced hypertro-
phy in vivo, indicating a role of this isotype in agonist-induced
cardiac hypertrophy [33]. More recently Crackower et al.
demonstrated that PI 3 kinaseQ negatively regulates myocytes
contractility in the absence of exogenous agonists [34]. How-
ever, we present the ¢rst evidence that PI 3 kinase positively
regulates BMP-2-induced shortening of cardiomyocytes (Figs.
2 and 3). Multiple targets of PI 3 kinase have been identi¢ed
including phosphoinositide-dependent kinase 1, Akt, MEK
and novel and atypical forms of protein kinase C [19,35^39].
In cardiomyocytes the target of PI 3 kinase that modulates
shortening has not yet been identi¢ed.
The osteogenic function of BMP-2 in bone fracture and
osteoporosis has been proposed. During the course of many
heart diseases, progressive decrease in myocyte contractility
ultimately leads to chronic heart failure. Our ¢nding that
BMP-2 stimulates myocytes shortening indicates that this
growth and di¡erentiation factor may be used as therapeutic
molecule in restoring cardiomyocyte function where mechan-
ical contractility is the cause of reduced heart function.
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